Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Emergent BioSolutions Inc.
Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine rBOT and Next Generation Anthrax Vaccine NGAV Candidates
August 13th, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases (NIAID) to fund the continued development of the company's rBOT and NGAV vaccine candidates. The rBOT grant is for the continued development, over a three-year period, of a serotype A and B recombinant botulinum vaccine. This is the first grant that Emergent BioSolutions has received for its botulinum vaccine program, and such support signals the U.S. government's confidence in the candidate. The NGAV grant provides important funding, over a five-year period, for animal model...
Source: Vaccine Weekly (2008-08-13)
|
